Biogen Company IP News and Updates

As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent...

By now, other commentators have posted on this Fed. Cir. decision (Appeal no. 2019 -1133, Sept. 28, 2020)—and found it...

CASE OF THE WEEK GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., Appeal No. 2018-1976, -2023 (Fed. Cir. Oct. 2, 2020)...

BIOGEN MA INC. v. EMD SERONO, INC. Before Newman, Linn, and Hughes.  Appeal from the District Court of the District...

The disclosure requirements that will meet the written description requirement of s. 112(1) had a fairly mundane priority policing role...

Written by Scott Siera, Ph.D. and Michael L. Fuller Stanford University v. The Chinese University of Hong Kong. Federal Circuit...